Medicamen Biotech Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech's Board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations stood at Rs 3,844.90 lakhs, down from Rs 4,148.17 lakhs in Q1 FY25, while net profit fell to Rs 163.66 lakhs from Rs 225.75 lakhs, a decline of roughly 27%. Consolidated net profit also dropped to Rs 160.05 lakhs from Rs 240.44 lakhs a year ago. The Board also approved the draft Annual Report for FY25, recommended a final dividend of Re. 1 per share (10%) subject to shareholder approval, and fixed the 32nd AGM for September 26, 2025. Three director changes were cleared: Mr. Ashwani Kumar Sharma was redesignated as Whole-time/Executive Director, and Mr. Sham Goel and Mr. Shaival Saurabh were appointed as Non-Executive Independent Directors for 5-year terms. The statutory auditor issued an unmodified (clean) limited review opinion on the results.
The quarter-on-quarter decline in both revenue and profit is a mild negative for the stock, but the results are in line with broader pharma sector softness. Director refresh and the proposed dividend are routine governance positives with limited price impact.